{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc.imfinzi:1 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc.imfinzi%3A1",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003655,
    "timestamp_received": "2026-04-06T14:50:53.374183+00:00Z",
    "timestamp_returned": "2026-04-06T14:50:53.377838+00:00Z",
    "trace_id": "64b8e331-6f44-4d43-acf0-dde8aa673936"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "ind:hc.imfinzi:1",
      "indication": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",
      "raw_biomarkers": "mismatch repair deficient (dMMR)",
      "raw_cancer_type": "primary advanced or recurrent endometrial cancer",
      "raw_therapeutics": "Imfinzi (durvalumab), carboplatin, paclitaxel",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hc.imfinzi",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Imfinzi (durvalumab) [product monograph]. HC.",
        "title": null,
        "aliases": [],
        "description": "AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.",
        "urls": [
          "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736",
          "https://pdf.hres.ca/dpd_pm/00080178.PDF"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hc",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Canada",
              "description": "Regulatory agency that approves drugs for sale and use in Canada.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-06-11",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://health-products.canada.ca/dpd-bdpp/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "AstraZeneca Canada Inc.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Imfinzi",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "durvalumab",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2017-11-03",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-04-10",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}